Gil-Nagel, Antonio
Sánchez-Carpintero, Rocío
Villanueva, Vicente
Funding for this research was provided by:
GW Pharmaceuticals
Article History
Received: 2 August 2022
Accepted: 20 February 2023
First Online: 27 February 2023
Competing interests
: Antonio Gil-Nagel has received honoraria and/or research funds from Arvelle/Angelini, Bial, Biocodex, EISAI, Esteve, GW Pharma, Jazz Pharmaceuticals, PTC Therapeutics, Stoke, UCB Pharma and Zogenix; Rocío Sánchez-Carpintero has received honoraria and/or research funds from Biocodex, GW Pharma, Jazz Pharmaceuticals and Zogenix; Vicente Villanueva has received honoraria and/or research funds from Angelini, Bial, Eisai, Esteve, GW Pharma, NewBridge, Novartis, Takeda, UCB Pharma and Zogenix.